Indication of autologous stem cell transplantation in chronic inflammatory demyelinating polyneuropathy: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)

Chronic Inflammatory Demyelinoting Polyneuropothy (OOP) is a chronic outoimmune disease involving the peripheral nervous system, characterized by focal and segmental demyelinotion accounting for neurological deficit. Clop diagnosis is based on several criteria and requires the presence of specific clinical symptoms and of demyelinating criteria on the electroneuromyogrom (ENMG) or of additional supportive criteria (spinal fluid examination with dissociation between albumin level and cellular abnormalities, nervous abnormalities on MRI or other minor abnormalities on ENMG, demyelinating features on nerve biopsy or patient improvement under socalled first-line therapy with immunodulator treatment). After failure of two successive first line immunomodulating drug therapies (corticosteroids, immunomodulating immunoglobulins, or plasma exchange), several options con be considered as second line therapies. The efficacy of autologous hematopoietic cell transplantation (AHCT) hos been shown in CIDP patients. The aim of these recommendations established by a working group of experts from the "Societe francaise de greffe de moelle osseuse et therapie celluloire (SFGM-TC)", the group "maladies auto-immunes et therapie celluloire (MATHEC)" and the "filiere de sante maladies rares neuromusculaire (FIINEMUS)" is to specify the eligibility criteria for AHCT in CND patients, to describe the mobilization and the conditioning regimen for the AHCT procedure, as well os the patient standardized post-transplant follow-up and the management of neurological treatment throughout the all procedure.